Shilpa Medicare received CDSCO authorisation for OERIS

Shilpa Medicare Limited received final marketing authorisation from the Central Drugs Standard Control Organisation for OERIS, an extended-release ondansetron injection. The approval includes patent protection in India until 2039. The development is relevant because OERIS uses an extended-release formulation of ondansetron, a drug used to prevent nausea and vomiting. The long patent period provides Shilpa Medicare with a defined period of market protection, although the eventual commercial contribution will depend on launch timing, pricing, distribution and prescription adoption. The stock was already showing strong price action before the latest update. Market data showed Shilpa Medicare closing at ₹1,021.10 in the previous session, up 6.55%, while the September 21 session continued to attract attention around the approval. view: the approval is more meaningful than a routine regulatory update because it gives the company an additional commercial product with a long stated patent period. However, regulatory approval should not be equated with immediate earnings. Investors still need to see how quickly the product is launched, what pricing it achieves and how much revenue it contributes. There is also a risk factor to monitor. The company's Hyderabad facility received one procedural observation during a recent USFDA surveillance inspection, according to the same market report. The company will need to address the observation through the appropriate corrective process. From a technical perspective, ₹1,021 becomes an important reference after the previous session's strong move. Sustaining above ₹1,000 would keep the recent price structure stronger. A move above the recent high with volume would indicate continued buying interest, while a reversal below ₹1,000 would suggest profit booking after the sharp rise. Call: Watch whether the CDSCO approval translates into actual commercial traction while monitoring the ₹1,000 zone for price stability.